Evidence map›Paper›PMID 39371804›Full record

ArticleCureus2024

Achieving a Pathologic Complete Response for Locally Advanced Esophageal Adenocarcinoma Using Cone-Beam Computed Tomography-Based Online Adaptive Radiotherapy.

Nicolas Bachmann, Daniel Schmidhalter, Frédéric Corminboeuf, Ekin Ermis, Daniel M Aebersold, Peter Manser, Hossein Hemmatazad

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nicolas BachmannDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, CHE.
Daniel SchmidhalterDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, CHE.
Frédéric CorminboeufDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, CHE.
Ekin ErmisDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, CHE.
Daniel M AebersoldDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, CHE.
Peter ManserDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, CHE.
Hossein HemmatazadDepartment of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, CHE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neo-adjuvant chemoradiotherapy (CRT) and perioperative chemotherapy are different strategies for treating non-metastatic esophageal cancer (EC). The advantages of neo-adjuvant therapies are primarily seen in patients who achieve a pathologic complete response (pCR) and therefore show higher survival rates and better prognosis. In general, less than one-third of patients with EC experience pCR after neo-adjuvant therapies; however, patients with esophageal adenocarcinoma (AC) demonstrate lower rates of pCR compared to those with esophageal squamous cell carcinoma (SCC), respectively. Herein, we describe two cases of locally advanced esophageal AC treated with cone-beam computed tomography (CBCT)-based online adaptive radiotherapy (ART) on the ETHOS platform. Both patients received CRT with 50.4 Gy in 28 fractions, combined with weekly carboplatin and paclitaxel. For each fraction, we evaluated scheduled and adapted plans using dose-volume histogram (DVH) data, and patients were treated with the superior plan. We prioritized ensuring optimal coverage of the planning target volume (PTV) over limiting the dose to organs at risk (OARs) when selecting the superior treatment plan. In this instance, we present the translation of superior dosimetric data into clinical benefits, as evidenced by an excellent pathologic response.

Indexed as

dosimetric parameterslocally advanced esophageal cancerneo-adjuvant radiochemotherapyonline-adaptive radiotherapypathologic complete response

Identifiers

PMID39371804
PMCPMC11456338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.